BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.
| SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- BridGene Biosciences, Inc. a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.
Pharmacological inhibitors of TEAD transcription factors have emerged as a promising novel class of anti-cancer agents. TEAD inhibitors disrupt oncogenic YAP/TAZ signaling, resulting in cell cycle arrest and cell death in susceptible cancers. “Using our IMTAC™ live-cell chemoproteomic platform to identify small molecules against challenging targets, we have successfully identified several potent and drug-like covalent ligands for TEAD. Based on this discovery, we rapidly developed the pre-clinical candidate BGI-9004,” said Wolf Wiedemeyer, Ph.D., BridGene’s head of biology. “The covalent TEAD inhibitor BGI-9004 has demonstrated promising activity both as a single agent and in combination with other targeted agents, a favorable pharmacokinetic profile and high target selectivity in preclinical models, supporting its evaluation as a novel anti-cancer agent in clinical trials.” Details regarding the poster presentation are as follows:
About BridGene Biosciences Contact Tiberend Strategic Advisors, Inc. Media Dave Schemelia
SOURCE BridGene Biosciences |
View original content to download multimedia:
